Joshua Brody, Associate Professor, Division of Hematology and Oncology at Icahn School of Medicine at Mount Sinai, shared on LinkedIn:
“Bullet point highlights from ASH25 on immunotherapy and therapies for T cell and B cell lymphoma targeting ITK and CD5 and CD19 and CD20 for B cell lymphomas, so cool!”
More posts about ASH25.